First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Kan Yonemori et al.|Clinical Cancer Research|2021Cited by 97
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculatureKatherine A. Rybinski, Yuhong Zhou, Hongxia Z. Imtiyaz et al.|Oncotarget|2015Cited by 48